6.6 Post-Cardiac Arrest Care and Targeted Temperature Management

6.6 Post-Cardiac Arrest Care and Targeted Temperature Management

The return of spontaneous circulation (ROSC) is not the end of resuscitation; it is the beginning of the post-cardiac arrest care phase. Critical care transport crews must manage the complex pathophysiology of Post-Cardiac Arrest Syndrome (PCAS) to prevent secondary brain injury, optimize systemic hemodynamics, and identify the precipitating cause. Targeted Temperature Management (TTM) is a key neuroprotective intervention during this phase.

Post-Cardiac Arrest Syndrome (PCAS)

PCAS is a multi-organ pathological process triggered by global ischemia and subsequent reperfusion. It consists of four main components:

1. Post-Cardiac Arrest Brain Injury: Characterized by cerebral edema, microvascular hypoperfusion, impaired autoregulation, and excitotoxicity (massive intracellular calcium influx and glutamate release). This is the leading cause of death in out-of-hospital cardiac arrest.
2. Post-Cardiac Arrest Myocardial Dysfunction: A transient myocardial stunning that leads to low cardiac output and arrhythmias, peaking 24 to 72 hours post-ROSC.
3. Systemic Ischemia-Reperfusion Response: A widespread inflammatory cascade resembling septic shock, characterized by vasodilation, endothelial activation, and microvascular clotting.
4. Persistent Precipitating Pathology: The underlying cause of the arrest (e.g., acute coronary occlusion, pulmonary embolism, toxic ingestion).

Targeted Temperature Management (TTM) Protocols

TTM is indicated for adult patients who achieve ROSC but remain comatose (unable to follow verbal commands). The goal is to mitigate reperfusion injury by decreasing cerebral oxygen consumption ($CMRO_2$ drops by 6% to 8% for every 1°C decrease in core temperature), stabilizing cellular membranes, and reducing the release of free radicals.

Protocol Parameters

• Target Temperature: A constant temperature between 32°C and 36°C is selected based on institutional protocol and maintained for at least 24 hours.
• Induction: Initiated as soon as possible. Methods include cold crystalloid infusions (30 mL/kg of 4°C saline), surface cooling devices, and ice packs.
• Rewarming: Must be slow and controlled, at a rate of 0.25°C to 0.5°C per hour. Rapid rewarming causes rapid peripheral vasodilation (causing severe shock), cellular electrolyte shifts (rebound hyperkalemia), and increased intracranial pressure.

Physiological Consequences and Complications of Hypothermia

Hypothermia affects every organ system. Transport crews must anticipate and manage these changes:

• Shivering: The body's thermoregulatory reflex to cold. Shivering increases metabolic rate and oxygen consumption by up to 500%, generating heat and carbon dioxide while raising intracranial pressure, which negates the benefits of TTM.
  • Management: A multimodal shivering protocol is required.
    • Tier 1: Skin counter-warming (applying heat packs to hands/face/feet to trick the hypothalamus), magnesium sulfate (target blood levels 3–4 mEq/L to lower the shivering threshold), and buspirone.
    • Tier 2: Sedative infusions (propofol, dexmedetomidine) and analgesics (fentanyl).
    • Tier 3: Neuromuscular blocking agents (e.g., vecuronium, cisatracurium). Note: Paralytics must only be used if the patient is fully sedated.
• Electrolyte Dynamics:
  • Cooling Phase: Hypothermia causes a "cold diuresis" due to vasoconstriction-induced increase in central venous volume, which inhibits antidiuretic hormone (ADH) and increases renal excretion of water and electrolytes. Concurrently, potassium, magnesium, and phosphate shift intracellularly, leading to hypokalemia.
  • Rewarming Phase: As the patient warms, these electrolytes shift back into the extracellular space. Aggressive potassium replacement during the cooling phase must be avoided, as it leads to severe, life-threatening rebound hyperkalemia during rewarming.
• Cardiovascular: Hypothermia decreases SA node depolarization, causing a physiologic sinus bradycardia. This bradycardia is protective (reduces myocardial oxygen demand) and does not require treatment unless accompanied by systemic hypoperfusion. PR, QRS, and QT intervals are prolonged, and Osborn (J) waves (a positive deflection at the junction of the QRS complex and ST segment) may appear on the ECG.
• Coagulopathy & Metabolism: Cold temperatures inhibit the coagulation cascade and impair platelet function, increasing bleeding risk. Insulin release is inhibited and insulin resistance is increased, causing hyperglycemia. Additionally, drug clearance is significantly delayed; the half-lives of sedatives, paralytics, and analgesics are often doubled, leading to prolonged drug effects.

Ventilation, Oxygenation, and Hemodynamic Goals

• Avoid Hyperoxia: Reperfusion with high concentrations of oxygen generates reactive oxygen species (free radicals), which damage brain tissue. Titrate $FiO_2$ to maintain an $SpO_2$ of 92% to 98% or a $PaO_2$ of 75 to 100 mmHg.
• Avoid Hyperventilation: Hyperventilation reduces $PaCO_2$ (hypocapnia), causing cerebral vasoconstriction. This severely reduces cerebral blood flow and worsens ischemic brain injury. Target normocapnia ($PaCO_2$ of 35 to 45 mmHg or $PetCO_2$ of 35 to 40 mmHg).
  • Blood Gas Correction: Blood gas analyzers heat blood to 37°C. In a hypothermic patient, uncorrected (alpha-stat) gas measurements will differ from temperature-corrected (pH-stat) measurements. Standard transport protocols recommend using alpha-stat (uncorrected) values to titrate ventilation.
• Hemodynamic Target: Maintain a MAP > 65 mmHg (often targeted to > 80 mmHg in patients with impaired cerebral autoregulation to maintain cerebral perfusion pressure). Use norepinephrine or epinephrine infusions to support perfusion.
• Immediate 12-Lead ECG: If STEMI or high suspicion of acute coronary occlusion is present, transport directly to a facility capable of immediate coronary angiography/percutaneous coronary intervention (PCI).